scholarly journals Obstructive Uropathy as a Major Presentation of Ovarian Clear Cell Adenocarcinoma

2008 ◽  
Vol 47 (1) ◽  
pp. 116-119
Author(s):  
Yen-Hua Huang ◽  
Tien-Shan Wei ◽  
Pao-Jen Chen ◽  
Shuenn-Dyh Chang ◽  
Tony Wing-Cheong Chi ◽  
...  
Keyword(s):  
Clear Cell ◽  
Obstructive Uropathy ◽  
Clear Cell Adenocarcinoma ◽  
Ovarian Clear Cell Adenocarcinoma

Two cases of ovarian clear cell adenocarcinoma producing estradiol

2012 ◽  
Vol 62 (3) ◽  
pp. 216-218 ◽  
Author(s):  
Tomohito Tanaka ◽  
Takayoshi Kanda ◽  
Satoru Munakata ◽  
Shigeki Fujita ◽  
Masahide Ohmichi
Keyword(s):  
Clear Cell ◽  
Clear Cell Adenocarcinoma ◽  
Ovarian Clear Cell Adenocarcinoma

Validation of the Histologic Grading for Ovarian Clear Cell Adenocarcinoma

2011 ◽  
Vol 0 (0) ◽  
pp. 129-138 ◽  
Author(s):  
Sohei Yamamoto ◽  
Atsuko Kasajima ◽  
Masashi Takano ◽  
Nobuo Yaegashi ◽  
Hiroyuki Fujiwara ◽  
...  
Keyword(s):  
Clear Cell ◽  
Clear Cell Adenocarcinoma ◽  
Ovarian Clear Cell Adenocarcinoma ◽  
Histologic Grading

Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma

2008 ◽  
Vol 18 (5) ◽  
pp. 934-936 ◽  
Author(s):  
J. A. Rauh-Hain ◽  
R. T. Penson
Keyword(s):  
Kinase Inhibitor ◽  
Clear Cell ◽  
Growth Factor Receptor ◽  
Cystic Degeneration ◽  
Clear Cell Adenocarcinoma ◽  
Vascular Endothelial ◽  
Ovarian Clear Cell Adenocarcinoma ◽  
Stage Ia ◽  
Endothelial Growth Factor ◽  
Similar Gene

Ovarian clear cell adenocarcinoma (OCCA) is a unique biological subtype of epithelial ovarian cancer, with a similar gene profile to renal cell carcinoma (RCC). Sunitinib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with proven antitumor activity in RCC and a rational biological option for treatment of OCCA. A 60-year-old woman presented with recurrent and refractory stage IA OCCA, after 9 years of remission. Sunitinib was initiated as fifth-line chemotherapy, associated with cystic degeneration of liver metastasis and a short downward trend in her CA125 level. Recurrent and refractory OCCA may respond to Sunitinib. Clinical trials are needed to objectively confirm these findings, as benefit may be limited in patients with extensively pretreated tumors

ABCF2 is a new biomarker of ovarian clear cell adenocarcinoma

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 5050-5050
Author(s):  
S. Nishimura ◽  
H. Tsuda ◽  
Y. M. Ito ◽  
K. Ito ◽  
N. Yaegashi ◽  
...  
Keyword(s):  
Clear Cell ◽  
Clear Cell Adenocarcinoma ◽  
Ovarian Clear Cell Adenocarcinoma

SUV max of FDG-PET/CT as a prognostic factor in ovarian clear cell adenocarcinoma.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e16509-e16509 ◽  
Author(s):  
Kazuhiro Takehara ◽  
Haruhisa Konishi ◽  
Atsumi Kojima ◽  
Shinichi Okame ◽  
Yuko Shiroyama ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Fdg Pet ◽  
Clear Cell ◽  
Clear Cell Adenocarcinoma ◽  
Ovarian Clear Cell Adenocarcinoma ◽  
Pet Ct ◽  
Fdg Pet Ct
Sign in / Sign up

Export Citation Format

Share Document